Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

Abstract

Background: Preterm infants exhibit an increased susceptibility to infections. To assess the contribution of adaptive immunity to this vulnerability, it is crucial to study its postnatal development. Objectives: We sought to define profiles of adaptive immune-cell subsets in large cohorts of preterm infants, investigating the influence of gestational age (GA) and perinatal factors on their development. Methods: Two German tertiary care neonatal intensive care unit cohorts (cohort 1: n = 499; cohort 2: n = 78) of hospitalized preterm infants (GA, 22.9-36.4 weeks) underwent flow cytometric phenotyping of peripheral blood lymphocyte subsets within the first 49 days of life. MetadeconfoundR package was used to evaluate (confounding) effects of clinical conditions on lymphocyte profiles. Results: GA at birth was a primary determinant of profiles of lymphocyte subsets. The most premature infants displayed persistently lower CD4+ TH-cell frequencies, an early transient increase in B cells, and a later expansion of natural killer cells (TH-low B-high natural killer–high phenotype). Detailed analysis revealed a less naive but more effector and regulatory CD4+ T-cell phenotype in preterm infants with lower GA at birth. Amniotic infection syndrome further accentuated this “premature” immune profile, which was also more prevalent in infants with typical complications of prematurity. In contrast, female sex was associated with higher CD4+ TH-cell frequencies. Conclusions: This study provides a comprehensive characterization of adaptive immune development in hospitalized preterm infants during the first weeks of life, demonstrating a strong dependence on GA and modulation by perinatal factors. The identified distinct developmental profiles offer a valuable reference framework for interpreting immune phenotyping data and highlight potential associations between immunologic immaturity and clinical outcomes in this vulnerable population.

OriginalspracheEnglisch
ZeitschriftJournal of Allergy and Clinical Immunology
Jahrgang157
Ausgabenummer2
Seiten (von - bis)506-516
Seitenumfang11
ISSN0091-6749
DOIs
PublikationsstatusVeröffentlicht - 01.2025

Fördermittel

This work was supported by grants of the German Center for Infection Research (DZIF) (grant no. TI 07.001_007 to J.D., C.H., and J.R.; individual grants to J.M., I.F., and J.P.). It was further supported by the Interdisciplinary Center for Clinical Research (IZKF) at the University of Würzburg (grant no. Z-3 BC-13 to J.D.). This work was supported by grants from the German Federal Ministry of Education and Research (BMBF) (PROSPER grant no. 01EK2103A to D.V. and C.H.; Advanced Clinician Scientist-Program INTERACT grant no. 01EO2108 to H.M.). It was further supported by grants from the German Research Foundation (DFG) (grant nos. VI 538/6-3 and VI 538-9-1 to D.V., and further by the DFG SFB grant no. 1583/1 [“DECIDE”] project no. 492620490, the DFG TRR grant no. 359 (“PILOT”) project no. 491676693, and DFG Germany's Excellence Strategy—EXC 2155 “RESIST”—Project ID 390874280; grant no. DFG-HA-6409-5/1 to C.H.; SFB grant no. 1665-515637292, “Sexdiversity,” to W.G.). I.F. is supported by the Section of Medicine, University of Lübeck, in the Advanced Clinician Scientist-Program LACS02-2024. I.F. reported receiving travel grants and speaker honoraria from Chiesi outside the submitted work. J.M. is supported by the Else Kröner-Fresenius Foundation. Part of the data will be presented at the 1st PRIMAL meeting (DFG-HA-6409-9/1). The funding agencies had no role in the design and conduct of the study.

TrägerTrägernummer
Deutsche Forschungsgemeinschaft390874280, 1583/1, 359, 491676693, VI 538/6-3, 492620490, EXC 2155, VI 538-9-1, 1665-515637292, DFG-HA-6409-5/1
Bundesministerium für Bildung und Forschung01EK2103A, 01EO2108
Julius-Maximilians-Universität WürzburgZ-3 BC-13
Deutsches Zentrum für InfektionsforschungTI 07.001_007
Else Kröner-Fresenius-StiftungDFG-HA-6409-9/1

    UN SDGs

    Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

    1. SDG 3 – Gesundheit und Wohlergehen
      SDG 3 – Gesundheit und Wohlergehen

    Strategische Forschungsbereiche und Zentren

    • Forschungsschwerpunkt: Infektion und Entzündung - Zentrum für Infektions- und Entzündungsforschung Lübeck (ZIEL)

    DFG-Fachsystematik

    • 2.21-03 Medizinische Mikrobiologie und Mykologie, Hygiene, Molekulare Infektionsbiologie
    • 2.22-20 Kinder- und Jugendmedizin
    • 2.21-05 Immunologie
    • 2.22-02 Public Health, gesundheitsbezogene Versorgungsforschung, Sozial- und Arbeitsmedizin
    • 2.22-21 Gynäkologie und Geburtshilfe
    • 2.22-22 Klinische Immunologie und Allergologie

    Fingerprint

    Untersuchen Sie die Forschungsthemen von „Effect of gestational age on lymphocyte phenotypes in hospitalized preterm infants“. Zusammen bilden sie einen einzigartigen Fingerprint.

    Zitieren